T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained antitumour immune responses. However, identifying predictive biomarkers that quantify T cell infiltration and the presence of proinflammatory TMEs associated with immune-checkpoint inhibitor (ICI) response for clinical implementation has proved challenging. Here, we highlight a study that validates a T cell-to-stroma enrichment score generated from RNA sequencing data as a novel biomarker for ICI response in patients with urothelial carcinoma.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rijnders, M. et al. Gene-expression-based T-cell-to-stroma enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer. Nat. Commun. 15, 1349 (2024).
Galsky, M. D. et al. Extended follow-up results from the CheckMate 274 trial. J. Clin. Oncol. 41, LBA443 (2023).
Apolo, A. B. et al. AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. J. Clin. Oncol. 42, LBA531 (2024).
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
Banchereau, R. et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat. Commun. 12, 3969 (2021).
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Powles, T. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 25, 1706–1714 (2019).
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875–888 (2024).
Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825–2834 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.A. has acted as a consultant and/or advisor of Astellas, BMS, Century Therapuetics and has received research funding from Astellas, Merck and Seagen. J.R. has acted as a consultant and/or advisor of Aadi Biosciences, Aktis, Alligator Biosciences, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, BMS, Boehringer Ingelheim, Century Therapeutics, EMD-Serono, Gilead, Hengrui, Imvax, Janssen, Loxo, Merck, Pfizer, Seagen and Tyra Biosciences and has received research funding from Acrivon, Astellas, AstraZeneca, Bayer, Loxo and Seagen.
Rights and permissions
About this article
Cite this article
Aggen, D.H., Rosenberg, J.E. Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00890-2
Published:
DOI: https://doi.org/10.1038/s41571-024-00890-2
